BridgeMD
New treatment option for Tirzepatide
Official title Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
ClinicalTrials.gov ID: NCT07423247
What this study is testing
What is Tirzepatide?
Tirzepatide is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for tirzepatide.
Also referred to as Spartina.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Post-transplant obesity is a common complication after kidney transplantation, largely attributed to recovery from uremia, increased appetite, sedentary lifestyle, and long-term corticosteroid exposure. Obesity in kidney transplant recipients increases the risk of cardiovascular disease, post-transplant diabetes mellitus (PTDM), and may contribute to graft injury through hyperfiltration-related mechanisms, potentially leading to reduced graft survival.
- Phase 4: studies an already-approved treatment
- Time commitment: about 24 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Kidney transplant recipient with ≥12 months since transplantation
- BMI ≥ 27 kg/m²
- Stable graft function in the last 3 months (serum creatinine variation \< 20%)
- Stable immunosuppressive regimen
You likely can't join if
- History of pancreatitis
- Severe gastroparesis
- History of medullary thyroid carcinoma (MTC) or MEN2 syndrome
- eGFR \< 30 mL/min/1.73m²
- Acute rejection episode within the past 6 months
- Any condition judged by the investigator to interfere with study participation or safety
See the full eligibility criteria
- Age ≥ 18 years
- Kidney transplant recipient with ≥12 months since transplantation
- BMI ≥ 27 kg/m²
- Stable graft function in the last 3 months (serum creatinine variation \< 20%)
- Stable immunosuppressive regimen
- Ability to provide written informed consent
- History of pancreatitis
- Severe gastroparesis
- History of medullary thyroid carcinoma (MTC) or MEN2 syndrome
- eGFR \< 30 mL/min/1.73m²
- Acute rejection episode within the past 6 months
- Any condition judged by the investigator to interfere with study participation or safety
The study team makes the final eligibility decision.
Where it's taking place
- Tehran, Iran
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 24 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tehran, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.